Jung Haiyoung, Yoon Suk Ran, Lim Jeewon, Cho Hee Jun, Lee Hee Gu
Immunotherapy Research Center, Korea Research Institute of Bioscience and Biotechnology, Daejeon 34141, Korea.
Department of Biomolecular Science, KRIBB School of Bioscience, Korea University of Science and Technology (UST), Yuseong-gu, Daejeon 34141, Korea.
Cancers (Basel). 2020 May 7;12(5):1179. doi: 10.3390/cancers12051179.
Rho GTPases play central roles in numerous cellular processes, including cell motility, cell polarity, and cell cycle progression, by regulating actin cytoskeletal dynamics and cell adhesion. Dysregulation of Rho GTPase signaling is observed in a broad range of human cancers, and is associated with cancer development and malignant phenotypes, including metastasis and chemoresistance. Rho GTPase activity is precisely controlled by guanine nucleotide exchange factors, GTPase-activating proteins, and guanine nucleotide dissociation inhibitors. Recent evidence demonstrates that it is also regulated by post-translational modifications, such as phosphorylation, ubiquitination, and sumoylation. Here, we review the current knowledge on the role of Rho GTPases, and the precise mechanisms controlling their activity in the regulation of cancer progression. In addition, we discuss targeting strategies for the development of new drugs to improve cancer therapy.
Rho GTPases通过调节肌动蛋白细胞骨架动力学和细胞黏附,在众多细胞过程中发挥核心作用,包括细胞运动、细胞极性和细胞周期进程。在多种人类癌症中均观察到Rho GTPase信号传导失调,且其与癌症发展及恶性表型相关,包括转移和化疗耐药性。Rho GTPase活性受鸟嘌呤核苷酸交换因子、GTP酶激活蛋白和鸟嘌呤核苷酸解离抑制剂精确调控。最近的证据表明,它还受翻译后修饰的调节,如磷酸化、泛素化和类泛素化。在此,我们综述了关于Rho GTPases作用的当前知识,以及在癌症进展调控中控制其活性的精确机制。此外,我们还讨论了开发新型药物以改善癌症治疗的靶向策略。